GSK plc (GSK)
Market Cap | 72.83B |
Revenue (ttm) | 41.97B |
Net Income (ttm) | 3.37B |
Shares Out | 4.08B |
EPS (ttm) | 0.81 |
PE Ratio | 21.64 |
Forward PE | 8.29 |
Dividend | $1.56 (4.29%) |
Ex-Dividend Date | Nov 15, 2024 |
Volume | 8,865,807 |
Open | 36.12 |
Previous Close | 36.66 |
Day's Range | 36.10 - 36.42 |
52-Week Range | 33.89 - 45.93 |
Beta | 0.33 |
Analysts | Hold |
Price Target | 48.00 (+32.27%) |
Earnings Date | Oct 30, 2024 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $48.0, which is an increase of 32.27% from the latest price.
News
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...
GSK plc (GSK) Q3 2024 Earnings Call Transcript
GSK plc (NYSE:GSK) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcar...
GSK: Earnings Confirm It's On Track To Meet Guidance
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS gr...
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 bill...
GSK Stock Drops as UK Firm Posts Underwhelming Results
GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.
GSK cuts vaccine sales target on reduced demand
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
GSK lowers 2024 vaccine sales forecast
GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for...
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio in...
New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024...
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caus...
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes ...
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits
Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn...
GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac
British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
GlaxoSmithKline Reaches $2.2 Billion Settlement in Zantac Lawsuits
GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlement...
GSK reaches up to $2.2 billion settlement in Zantac US state court cases
GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.
GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and Moderna
GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjust...
RSV Vaccine Demand Drops Sharply in the US, Impacting GSK's Sales
Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Mo...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons.